ZMapp - Information Sheet

ZMapp TM is the result of a collaboration between Mapp Biopharmaceutical Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).

ZMapp TM is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana.  It is an optimized cocktail combining the best components of MB-­‐003 (Mapp) and ZMAb (Defyrus/PHAC).

ZMapp TM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans.  As such very little of the drug is currently available.  

Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.

CLICK HERE - ZMapp - Information Sheet (1 page .PDF file)

http://www.mappbio.com/

As Mapp's products transition to clinical evaluation, licenses are transferred to Mapp's commercialization partner, LeafBio.

http://www.leafbio.com/